Impact of Anxiety or Depression Symptoms on Propofol Requirements for Sedation in Females: A Prospective Cohort Study.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1376, doi. 10.1002/jcph.1631
- By:
- Publication type:
- Article
Works matching IS 00912700 AND DT 2020 AND VI 60 AND IP 10
Results: 14
1
2
Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1324, doi. 10.1002/jcph.1623
- By:
- Publication type:
- Article
3
Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P‐Glycoprotein Inhibitor (Itraconazole).
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1314, doi. 10.1002/jcph.1628
- By:
- Publication type:
- Article
4
Issue Information.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1269, doi. 10.1002/jcph.1755
- Publication type:
- Article
5
A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1304, doi. 10.1002/jcph.1634
- By:
- Publication type:
- Article
6
Exposure‐Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1385, doi. 10.1002/jcph.1632
- By:
- Publication type:
- Article
7
Immunomodulatory Therapeutic Proteins in COVID‐19: Current Clinical Development and Clinical Pharmacology Considerations.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1275, doi. 10.1002/jcph.1729
- By:
- Publication type:
- Article
8
Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1397, doi. 10.1002/jcph.1636
- By:
- Publication type:
- Article
9
Rivaroxaban as an Alternative Agent for Heparin‐Induced Thrombocytopenia.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1362, doi. 10.1002/jcph.1635
- By:
- Publication type:
- Article
10
Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1334, doi. 10.1002/jcph.1626
- By:
- Publication type:
- Article
11
Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1355, doi. 10.1002/jcph.1625
- By:
- Publication type:
- Article
12
Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1344, doi. 10.1002/jcph.1624
- By:
- Publication type:
- Article
13
Suspected Adverse Drug Reactions From Corticosteroids: Analysis of Reported Notifications to the Portuguese Pharmacovigilance System.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1367, doi. 10.1002/jcph.1630
- By:
- Publication type:
- Article
14
Proposal of a Safe and Effective Study Design for CYP3A‐Mediated Drug‐Drug Interactions.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1294, doi. 10.1002/jcph.1622
- By:
- Publication type:
- Article